2026-04-14T04:06:17Zhttps://recercat.cat/oai/request

oai:recercat.cat:10459.1/4688422025-10-20T18:27:01Zcom_2072_3622col_2072_479130

2025-10-20T18:27:01Z urn:hdl:10459.1/468842 Agreement of cerebrospinal fluid biomarkers and amyloid-PET in a multicenter study Guillén, Núria Contador, José Buongiorno, Mariateresa Álvarez, Ignacio Culell, Natalia Alcolea, Daniel Lleó, Alberto Fortea, Juan Piñol Ripoll, Gerard Carnes Vendrell, Anna Lourdes Ispierto, María Vilas, Dolores Puig Pijoan, Albert Fernández Lebrero, Aida Balasa, Mircea Sánchez Valle, Raquel Lladó, Albert Alzheimer’s disease Amyloid-PET Biomarkers CSF Core Alzheimer's disease (AD) cerebrospinal fluid (CSF) biomarkers have shown incomplete agreement with amyloid-positron emission tomography (PET). Our goal was to analyze the agreement between AD CSF biomarkers and amyloid-PET in a multicenter study. Retrospective multicenter study (5 centers). Participants who underwent both CSF biomarkers and amyloid-PET scan within 18 months were included. Clinical diagnoses were made according to latest diagnostic criteria by the attending clinicians. CSF Amyloid Beta (Aβ, A), phosphorliated tau 181 (pTau181, T) and total tau (tTau, N) biomarkers were considered normal (-) or abnormal ( +) according to cutoffs of each center. Amyloid-PET was visually classified as positive/negative. Agreement between CSF biomarkers and amyloid-PET was analyzed by overall percent agreement (OPA). 236 participants were included (mean age 67.9 years (SD 9.1), MMSE score 24.5 (SD 4.1)). Diagnoses were mild cognitive impairment or dementia due to AD (49%), Lewy body dementia (22%), frontotemporal dementia (10%) and others (19%). Mean time between tests was 5.1 months (SD 4.1). OPA between single CSF biomarkers and amyloid-PET was 74% for , 75% for pTau181, 73% for tTau. The use of biomarker ratios improved OPA: 87% for Aβ/Aβ (n = 155), 88% for pTau181/Aβ (n = 94) and 82% for tTau/Aβ (n = 160). A + T + N + cases showed the highest agreement between CSF biomarkers and amyloid-PET (96%), followed by A-T-N- cases (89%). Aβ/Aβ was a better marker of cerebral amyloid deposition, as identified by amyloid tracers, than Aβ alone. Combined biomarkers in CSF predicted amyloid-PET result better than single biomarkers. Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. Instituto de Salud Carlos III, PI19/00449, Albert Lladó, FI20/00076, Núria Guillén Soley, PI18/00435, Daniel Alcolea,INT19/00016, Daniel Alcolea, PI17/01896,Alberto Lleó, AC19/00103, Alberto Lleó, PI14/01126, Juan Fortea,PI17/01019, Juan Fortea, PI20/01473, Juan Fortea,Departament de Salut,Generalitat de Catalunya, PERIS 2016-2020 SLT008/18/00061, Albert Lladó, PERIS 2019 SLT008/18/00050, Gerard Piñol-Ripoll, SLT006/17/125, Daniel Alcolea, PERIS SLT002/16/408, Alberto Lleó,AGAUR,Alberto Lleó,SLT006/17/119, Juan Fortea,Diputació de Lleida, PIRS2021, Gerard Piñol-Ripoll,Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Program 1, Alberto Lleó,Alzheimer Disease,Alberto Lleó,Fundació la Marató de TV3, 20142610,Alberto Lleó, 20141210,Juan Fortea,Fundación BBVA,Foundation for the National Institutes of Health,1R01AG056850-01A1, Juan Fortea, R21AG056974,Juan Fortea,R01AG061566, Juan Fortea, Fundació Docència i Recerca Mútua de Terrassa, 2022, Mariateresa Buongiorno 2025-10-20T18:27:01Z 2025-10-20T18:27:01Z 2025-01 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://hdl.handle.net/10459.1/468842 Reproducció del document publicat a: https://doi.org/10.1007/s00406-023-01701-y European Archives of Psychiatry and Clinical Neuroscience, 2025, vol. 275, núm. 1, p. 257–266 cc-by, (c) Núria Guillen et al., 2025 Attribution 4.0 International info:eu-repo/semantics/openAccess http://creativecommons.org/licenses/by/4.0/ Springer Nature